866-997-4948(US-Canada Toll Free)

Taxotere (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 32 Pages

 

GlobalDatas pharmaceuticals report, Taxotere (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Taxotere\'s sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Taxotere including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Taxotere including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Taxoterin each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Report Guidance 8


3 NSCLC: Market Characterization 9
3.1 NSCLC Market 9
3.2 NSCLC Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance therapy 11
3.3.5 Promising Pipeline Drugs 11


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Taxotere 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 As second-line treatment in comparison with best supportive care 15
5.3.2 As first-line treatment in comparison with vinorelbine and Cisplatin 15
5.4 Approval History of Taxotere 16
5.5 Factors Affecting Sales of Taxotere 16
5.5.1 NSCLC Market 16
5.5.2 High Efficacy 16
5.5.3 Toxic Deaths 17
5.5.4 Large Patient Pool 17
5.5.5 Patent Expiry 17
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 17
5.6.2 Safety 17
5.6.3 Compliance 18
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales forecast 18
5.8.1 Target patient Pool of Taxotere 18
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Taxotere 20


6 NSCLC Market: Appendix 28
6.1 Market Definitions 28
6.2 List of Abberiviations 28
6.3 Research Methodology 28
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 29
6.3.4 Number of Patients Approved to take the Drug 29
6.3.5 Net Penetration of Drug 30
6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 31
6.3.8 Primary Research 31
6.3.9 Expert Panels 31
6.4 Contact Us 32
6.5 Disclaimer 32
6.6 Sources 32

List of Table


Table 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Clinical Trial Results (second-line treatment) 15
Table 4: Clinical Trial Results (first-line treatment) 16
Table 5: Taxotere Approval History 16
Table 6: Drug Risk Benefit Score 17
Table 7: Annual Cost of Taxotere for First Line in 2009 19
Table 8: Annual Cost of Taxotere for Second Line in 2009 19
Table 9: Taxotere, NSCLC, the US, EU-5 and Japan, Estimated Sales($m), 2002-2017 20
Table 10: Taxotere, NSCLC, the US, Estimated Sales ($m), 2002-2015 21
Table 11: Taxotere, NSCLC, the UK, Estimated Sales($m), 2002-2015 22
Table 12: Taxotere, NSCLC, France, Estimated Sales($m), 2002-2015 23
Table 13: Taxotere, NSCLC, Germany, Estimated Sales($m), 2002-2015 24
Table 14: Taxotere,NSCLC, Italy, Estimated Sales($m), 2002-2015 25
Table 15: Taxotere, NSCLC, Spain, Estimated Sales($m), 2002-2015 26
Table 16: Taxotere,NSCLC, Japan, Estimated Sales($m), 2002-2017 27

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: Oncology, Global, Incidence (in millions), 2008-2030 10
Figure 8: NSCLC, Global, Incidence (in millions), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Target Patient Pool of Taxotere 18
Figure 13: Taxotere, NSCLC, the US, EU-5 and Japan, Estimated Sales($m), 2002-2017 20
Figure 14: Taxotere, NSCLC, the US, Estimated Sales($m), 2002-2015 21
Figure 15: Taxotere, NSCLC, the UK, Estimated Sales($m), 2002-2015 22
Figure 16: Taxotere, NSCLC, France, Estimated Sales($m), 2002-2015 23
Figure 17: Taxotere, NSCLC, Germany, Estimated Sales($m), 2002-2015 24
Figure 18: Taxotere, NSCLC, Italy, Estimated Sales($m), 2002-2015 25
Figure 19: Taxotere, NSCLC, Spain, Estimated Sales($m), 2002-2015 26
Figure 20: Taxotere,NSCLC, Japan, Estimated Sales($m), 2002-2017 27
Figure 21: GlobalData Methodology 28
Figure 22: Drug Model Diagram 30
Figure 23: Patients Approved for the Drug 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *